Zhang Yandi, Banga Ndzouboukou Jo-Lewis, Gan Mengze, Lin Xiaosong, Fan Xionglin
Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Immunol. 2021 Nov 22;12:771242. doi: 10.3389/fimmu.2021.771242. eCollection 2021.
Coronavirus disease 2019 (COVID-19) pandemic is a serious threat to global public health and social and economic development. Various vaccine platforms have been developed rapidly and unprecedentedly, and at least 16 vaccines receive emergency use authorization (EUA). However, the causative pathogen severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has continued to evolve and mutate, emerging lots of viral variants. Several variants have successfully become the predominant strains and spread all over the world because of their ability to evade the pre-existing immunity obtained after previous infections with prototype strain or immunizations. Here, we summarized the prevalence and biological structure of these variants and the efficacy of currently used vaccines against the SARS-CoV-2 variants to provide guidance on how to design vaccines more rationally against the variants.
2019年冠状病毒病(COVID-19)大流行对全球公共卫生以及社会和经济发展构成严重威胁。各种疫苗平台以前所未有的速度迅速开发出来,至少有16种疫苗获得了紧急使用授权(EUA)。然而,病原体严重急性呼吸综合征冠状病毒2(SARS-CoV-2)持续进化和变异,出现了许多病毒变种。由于能够逃避先前感染原型毒株或接种疫苗后获得的既往免疫力,几种变种已成功成为主要毒株并在全球传播。在此,我们总结了这些变种的流行情况、生物学结构以及目前使用的疫苗针对SARS-CoV-2变种的效力,以为更合理地设计针对变种的疫苗提供指导。